Cargando…

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab

Detalles Bibliográficos
Autores principales:	Gingele, Stefan, Skripuletz, Thomas, Jacobs, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975146/ https://www.ncbi.nlm.nih.gov/pubmed/31638088 http://dx.doi.org/10.4103/1673-5374.266913

Ejemplares similares

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill
por: Avasarala, Jagannadha
Publicado: (2017)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Mesenchymal stem cells require the peripheral immune system for immunomodulating effects in animal models of multiple sclerosis
por: Salinas Tejedor, Laura, et al.
Publicado: (2016)

Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis
por: Ho, Samantha, et al.
Publicado: (2023)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis
por: Konen, Franz Felix, et al.
Publicado: (2021)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
por: Daniels, K., et al.
Publicado: (2020)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Viral pericarditis following ocrelizumab in a multiple sclerosis patient
por: Miele, Giuseppina, et al.
Publicado: (2023)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
por: Martins, Paulo, et al.
Publicado: (2022)

Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis
por: Schwenkenbecher, Philipp, et al.
Publicado: (2019)

A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
por: Frisch, Esther S., et al.
Publicado: (2021)

Investigation of Oligoclonal IgG Bands in Tear Fluid of Multiple Sclerosis Patients
por: Hümmert, Martin W., et al.
Publicado: (2019)

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
por: Wolinsky, Jerry S, et al.
Publicado: (2020)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
por: Fernandez‐Diaz, Eva, et al.
Publicado: (2020)

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe
por: Aun, Marcelo Vivolo, et al.
Publicado: (2022)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
por: ROJAS, Juan Ignacio, et al.
Publicado: (2021)

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
por: Montalban, Xavier, et al.
Publicado: (2023)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hggil1rs82a3p9fvsdth4402a6